Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

New program aims to build and demonstrate ruggedized device for tactical applications.

Like.

Comment.

Linear accelerators, LINACs for short, are devices that accelerate electrons or other sub-atomic particles along a straight line to generate a beam of high energy. LINACs have a variety of commercial uses such as generating X-rays for cargo inspection, medical diagnostics, food sterilization, and even enabling precise external radiation treatments to destroy cancer cells without damaging surrounding tissue. To generate more powerful electron beams using current technology, however, requires building larger LINACs that can grow to dozens of meters or longer depending on the application. Unfortunately, powerful LINACs are too large and heavy to be practical for military use in the field.

DARPA has announced its Advanced Concept Compact Electron Linear-accelerator (ACCEL) program whose goal is to develop a powerful, deployable electron LINAC. A webinar Proposers Day for potential proposers is scheduled for January 282021.

“A high-power compact, rugged accelerator that could be transported by truck or aircraft to austere locations would provide multiple defense and homeland security benefits,” said Col. Dan “Animal” Javorsek, ACCEL program manager. “It could be used for medical treatments in locales without advanced hospitals, remote detonation of Improvised Explosive Devices, and mobile imaging or inspection of shipping containers’ contents to counter chem-bio and radiological threats. A deployable LINAC could also enable portable sterilization for foods and surfaces to prevent contamination and infection in deployed environments.”

Read more | >

DARPA Looks to Light up Integrated Photonics with Chip-Scale Laser DevelopmentAgency announces performer teams selected for LUMOS program.

Like.

Comment.

First demonstrated sixty years ago, the laser has become an essential technology in today’s world. It has transformed diverse fields including communications, sensing, manufacturing, and medicine. More recently, innovations in integrated photonics have allowed the miniaturization of key optical components and the ability to arrange several elements on a single silicon chip. When combined with lasers, these photonic integrated circuits (PICs) have the potential to replace large and costly optical systems with chip-scale solutions. However, due to differences in the properties of the materials that compose them, lasers and PICs are difficult to combine onto the same platform, limiting the benefits of integration and preventing broad technology impact.

To address this challenge, DARPA developed the Lasers for Universal Microscale Optical Systems (LUMOS) program, which aims to bring high-performance lasers to advanced photonics platforms. As highlighted in the recent program kick-off meeting, LUMOS will address several commercial and defense applications by directing efforts across three distinct Technical Areas.

The first LUMOS Technical Area brings high-performance lasers and optical amplifiers into advanced domestic photonics manufacturing foundries. Two research teams were selected in this area: Tower Semiconductor and SUNY Polytechnic Institute. These performers will work to demonstrate flexible, efficient on-chip optical gain in their photonics processes to enable next-generation optical microsystems for communications, computing, and sensing. LUMOS technologies will be made available to future design teams through DARPA-sponsored multi-project wafer runs.

Read more | >

Japan’s Prime Minister Yoshihide Suga has declared a state of emergency for the nation’s capital and surrounding areas as Covid-19 cases surge to the highest levels since the start of the pandemic.

The emergency declaration will be in place from Friday until February 7 and applies to Tokyo and the three neighboring prefectures of Chiba, Saitama and Kanagawa. The emergency includes a number of restrictions on daily life.

Suga has ordered companies to encourage their staff to work from home and reduce office populations by 70%.

Read more | >

Aging is, at least for now, inevitable, and our eyes are not immune to those changes. Vision loss is, in fact, one of the top 10 causes of disability in the US., however, shows that this might be reversible in the future.

A large team of geneticists, ophthalmologists, and other scientists used a group of molecules called Yamanaka factors to turn cells in the eyes of mature mice back to a youthful state. This reversed the damage done by aging, and the cells were then able to regenerate, connect back to the brain, and vision was restored in both models of normal aging and glaucoma.

Yamanaka factors are nothing new in neuroscience. They are named after the after Shinya Yamanaka led research using those factors to convert mature adult cells back to stem cells, kickstarting the field of induced pluripotent stem cells — cells reprogrammed with the ability to generate other types of cells.

Read more | >

Watch out, George Lucas, there’s a new attack of the clones, and these ones are furry.

Japanese researchers have created a potentially endless line of mice cloned from other cloned mice. They used the same technique that created Dolly the sheep to produce 581 mice from an original donor mouse through 25 rounds of cloning, the scientists report in the March 7 issue of the journal Cell Stem Cell.

“This technique could be very useful for the large-scale production of superior-quality animals, for farming or conservation purposes,” study leader Teruhiko Wakayama of the RIKEN Center for Developmental Biology in Kobe, Japan, said in a statement.

Read more | >

O,.o circa 2020.

Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a simple, high-throughput method for transferring isolated mitochondria and their associated mitochondrial DNA into mammalian cells. This approach enables researchers to tailor a key genetic component of cells, to study and potentially treat debilitating diseases such as cancer, diabetes and metabolic disorders.

A study, published today in the journal Cell Reports, describes how the new UCLA-developed device, called MitoPunch, transfers mitochondria into 100000 or more recipient cells simultaneously, which is a significant improvement from existing mitochondrial transfer technologies. The device is part of the continued effort by UCLA scientists to understand mutations in mitochondrial DNA by developing controlled, manipulative approaches that improve the function of human cells or model human mitochondrial diseases better.

The ability to generate cells with desired mitochondrial DNA sequences is powerful for studying how genomes in the mitochondria and nucleus interact to regulate cell functions, which can be critical for understanding and potentially treating diseases in patients.

Read more | >

In Michelle O’Malley’s lab, a simple approach suggests a big leap forward in addressing the challenge of antibiotic-resistant bacteria.

Scientists have long been aware of the dangerous overuse of antibiotics and the increasing number of antibiotic-resistant microbes that have resulted. While over-prescription of antibiotics for medicinal use has unsettling implications for human health, so too does the increasing presence of antibiotics in the natural environment. The latter may stem from the improper disposal of medicines, but also from the biotechnology field, which has depended on antibiotics as a selection device in the lab.

“In biotech, we have for a long time relied on antibiotic and chemical selections to kill cells that we don’t want to grow,” said UC Santa Barbara chemical engineer Michelle O’Malley. “If we have a genetically engineered cell and want to get only that cell to grow among a population of cells, we give it an antibiotic resistance gene. The introduction of an antibiotic will kill all the cells that are not genetically engineered and allow only the ones we want — the genetically modified organisms [GMOs] — to survive. However, many organisms have evolved the means to get around our antibiotics, and they are a growing problem in both the biotech world and in the natural environment. The issue of antibiotic resistance is a grand challenge of our time, one that is only growing in its importance.”

Read more | >